GMP Antibiotics Ceftazidime for Injection 1.0g Vial

• Customization: Available
• Application: Injection
• Usage Mode: IV
• Model NO.: 1.0g
• Suitable for: Adult
• State: Powder
• Shape: Powder
• Type: Biological Products
• Pharmaceutical Technology: Chemical Synthesis
• Molecular Formula: C22h22n6o7s2·5H2O
• Molecular Weight: 636.65
• Character: White or Almost White Crystalline Powder
• Transport Package: Cartoon
• Specification: 1.0g/10ml vial
• Trademark: Without
• Origin: China
• HS Code: 3004909099
• Production Capacity: 10000000 Vial Per Month

Product Description

 

Product Description

 

Ceftazidime for injection

Ingredients

The main ingredient of this product is ceftazidime, with appropriate amount of sodium carbonate as cosolvent


This product can be used for septicemia caused by sensitive gram-negative bacilli, infection of lower respiratory system, infection of celiac biliary system, complicated urinary tract infection and severe skin and soft tissue infection.
It is especially suitable for the infection of immunodeficient patients, hospital infection and central nervous system infection caused by Gram negative bacilli or Pseudomonas aeruginosa.

Usage and dosage

Before use, add a proper amount of sterile water for injection to make it dissolve.

Septicemia, lower respiratory system infection and biliary system infection were 4-6 g / day, divided into 2-3 times of intravenous drip or injection, and the course of treatment was 10-14 days.

Urinary tract infection and severe skin and soft tissue infection, 2-4G / day, two times of intravenous drip or injection, 7-14 days.

For some life-threatening infections, severe Pseudomonas aeruginosa infection and central nervous system infection, 150-200mg / kg per day may be taken in increments as appropriate, and intravenous drip or injection may be made three times.

The daily dosage of infants is 30-100mg / kg, divided into 2-3 intravenous drip, the maximum daily dose is not more than 6G.

 Usage and dosage

Before use, add a proper amount of sterile water for injection to make it dissolve.

Septicemia, lower respiratory system infection and biliary system infection were 4-6 g / day, divided into 2-3 times of intravenous drip or injection, and the course of treatment was 10-14 days.

Urinary tract infection and severe skin and soft tissue infection, 2-4G / day, two times of intravenous drip or injection, 7-14 days.

For some life-threatening infections, severe Pseudomonas aeruginosa infection and central nervous system infection, 150-200mg / kg per day may be taken in increments as appropriate, and intravenous drip or injection may be made three times.

The daily dosage of infants is 30-100mg / kg, divided into 2-3 intravenous drip, the maximum daily dose is not more than 6G.

Usage and dosage

Before use, add a proper amount of sterile water for injection to make it dissolve.

Septicemia, lower respiratory system infection and biliary system infection were 4-6 g / day, divided into 2-3 times of intravenous drip or injection, and the course of treatment was 10-14 days.

Urinary tract infection and severe skin and soft tissue infection, 2-4G / day, two times of intravenous drip or injection, 7-14 days.

For some life-threatening infections, severe Pseudomonas aeruginosa infection and central nervous system infection, 150-200mg / kg per day may be taken in increments as appropriate, and intravenous drip or injection may be made three times.

The daily dosage of infants is 30-100mg / kg, divided into 2-3 intravenous drip, the maximum daily dose is not more than 6G

 Adverse reaction

The adverse reactions of this product are rare and mild, the incidence is about 2.5%. A few patients developed skin rash (0.5% - 2%), pruritus and drug fever; nausea, diarrhea and abdominal pain; mild phlebitis at the injection site; occasionally, transient serum transaminase (SGPT), blood urea nitrogen and blood creatinine increased slightly; leucocyte, thrombocytopenia and eosinophilia increased. Mild or moderate reversible reduction in glomerular filtration rate during the course of treatment has also been reported. Coombs test was positive in 5% of patients, hemolytic anemia and thrombocytosis were rare, reversible neutropenia was seen in individual patients. The incidence of double infection was 2.5%. The common pathogens were Enterococcus and Candida.
 
 Contraindication

It is forbidden to use in those who have a history of allergic reaction to this product or cephalosporin antibiotics. Patients with a history of penicillin anaphylactic shock should avoid using this product.